Related Experiment Video
Updated: Jun 21, 2025
07:33
In vivo Dual Substrate Bioluminescent Imaging
Published on: October 11, 2011
15.6K
In vivo turnover and biodistribution of soluble AXL: implications for biomarker development
Olav Tenstad1, Eleni Christakou1,2, Linn Hodneland Nilsson2
1Department of Biomedicine, University of Bergen, Jonas Lies Vei 91, 5009, Bergen, Norway.
Scientific Reports
|July 12, 2024
Summary
The soluble AXL receptor (sAXL) biomarker
Area of Science:
- Biochemistry
- Molecular Biology
- Personalized Medicine
Background:
- Soluble biomarkers are crucial for personalized medicine.
- In vivo turnover and biodistribution of soluble proteins like sAXL are poorly understood.
- sAXL is a prognostic biomarker and predicts response to AXL-targeting therapies.
Purpose of the Study:
- To characterize the in vivo turnover and biodistribution of soluble AXL receptor (sAXL).
- To understand how sAXL transport dynamics influence plasma levels for biomarker development.
Main Methods:
- Radiolabeled mouse sAxl was administered intravenously and intradermally.
- Degradation, urinary excretion, and lymphatic transport of sAxl were monitored.
- The molecular structure of sAxl was analyzed.
Main Results:
- sAXL undergoes rapid uptake and degradation in the liver and kidney cortex.
- Intact sAXL is excreted in urine, indicating glomerular filtration.
- Intradermal sAXL showed lymphatic transport to lymph nodes, liver, and kidneys, with low plasma levels.
Conclusions:
- sAXL's molecular structure facilitates glomerular passage and urinary excretion.
- Plasma sAXL levels dynamically reflect tissue production but are sensitive to liver/kidney function.
- Understanding sAXL biodistribution is key for its use as a biomarker.
